Three TKIs, imatinib, dasatinib and nilotinib that target BCR-ABL are routinely given with success as first or second-line treatment for this disease, but resistance occurs in a significant proportion of CML patients [2-4]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.